A Randomized, Open-Label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naïve Subjects with Advanced or Metastatic PD-L1 High (TPS >/= 50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung08)

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination with Deruxtecan Antibody-drug Conjugates in Subjects with Solid Tumors

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer

A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors